BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA Removes BPC 157, TB 500 and 10 More Peptides from Category 2 (April 2026) Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter FDA Removes 12 Peptides from 503A Category 2 Newtropin